Vu HA - Search Results

1

Synergistic effect of all‑trans retinoic acid in combination with protein kinase C 412 in FMS-like tyrosine kinase 3-mutated acute myeloid leukemia cells.

Chi HT, Ly BT, Vu HA, Sato Y, Dung PC, Xinh PT. Chi HT, et al. Among authors: vu ha. Mol Med Rep. 2015 May;11(5):3969-75. doi: 10.3892/mmr.2015.3203. Epub 2015 Jan 15. Mol Med Rep. 2015. PMID: 25592076

2

A recurrent duodenal gastrointestinal stromal tumor with a frameshift mutation resulting in a stop codon in KIT exon 13.

Vu HA, Xinh PT, Kikushima M, Zhu Y, Tokuhara M, Tani M, Shimizu T, Saito K, Tokunaga K, Sato Y. Vu HA, et al. Genes Chromosomes Cancer. 2005 Feb;42(2):179-83. doi: 10.1002/gcc.20110. Genes Chromosomes Cancer. 2005. PMID: 15543597

3

Coexistence of Philadelphia chromosome positive cells with and without der(9) deletion in a patient with chronic myelogenous leukemia.

Xinh PT, Vu HA, Nghia H, Binh NT, Van Be T, Van Binh T, Tokunaga K, Sato Y. Xinh PT, et al. Among authors: vu ha. Cancer Genet Cytogenet. 2006 Jan 15;164(2):122-7. doi: 10.1016/j.cancergencyto.2005.07.012. Cancer Genet Cytogenet. 2006. PMID: 16434314

4

FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and a t(12;13)(p13;q12) translocation.

Vu HA, Xinh PT, Masuda M, Motoji T, Toyoda A, Sakaki Y, Tokunaga K, Sato Y. Vu HA, et al. Leukemia. 2006 Aug;20(8):1414-21. doi: 10.1038/sj.leu.2404266. Epub 2006 Jun 8. Leukemia. 2006. PMID: 16761019

5

Divergent cytotoxic effects of PKC412 in combination with conventional antileukemic agents in FLT3 mutation-positive versus -negative leukemia cell lines.

Furukawa Y, Vu HA, Akutsu M, Odgerel T, Izumi T, Tsunoda S, Matsuo Y, Kirito K, Sato Y, Mano H, Kano Y. Furukawa Y, et al. Among authors: vu ha. Leukemia. 2007 May;21(5):1005-14. doi: 10.1038/sj.leu.2404593. Epub 2007 Mar 1. Leukemia. 2007. PMID: 17330105

6

The juxtamembrane domain in ETV6/FLT3 is critical for PIM-1 up-regulation and cell proliferation.

Vu HA, Xinh PT, Kano Y, Tokunaga K, Sato Y. Vu HA, et al. Biochem Biophys Res Commun. 2009 Jun 5;383(3):308-13. doi: 10.1016/j.bbrc.2009.03.157. Epub 2009 Apr 5. Biochem Biophys Res Commun. 2009. PMID: 19345670

7

Cas-L was overexpressed in imatinib-resistant gastrointestinal stromal tumor cells.

Thao le B, Vu HA, Yasuda K, Taniguchi S, Yagasaki F, Taguchi T, Watanabe T, Sato Y. Thao le B, et al. Among authors: vu ha. Cancer Biol Ther. 2009 Apr;8(8):683-8. doi: 10.4161/cbt.8.8.7779. Cancer Biol Ther. 2009. PMID: 19417561 Free article.

8

Green tea (-)-epigalocatechin-3-gallate inhibits KIT activity and causes caspase-dependent cell death in gastrointestinal stromal tumor including imatinib-resistant cells.

Chi HT, Vu HA, Iwasaki R, Thao le B, Hara Y, Taguchi T, Watanabe T, Sato Y. Chi HT, et al. Among authors: vu ha. Cancer Biol Ther. 2009 Oct;8(20):1934-9. doi: 10.4161/cbt.8.20.9594. Epub 2009 Oct 22. Cancer Biol Ther. 2009. PMID: 19770581 Free article.

9

Detection of exon 12 type A mutation of NPM1 gene in IMS-M2 cell line.

Chi HT, Vu HA, Iwasaki R, Nagamura F, Tojo A, Watanabe T, Sato Y. Chi HT, et al. Among authors: vu ha. Leuk Res. 2010 Feb;34(2):261-2. doi: 10.1016/j.leukres.2009.09.019. Epub 2009 Oct 24. Leuk Res. 2010. PMID: 19854508

10

Green tea epigallocatechin gallate exhibits anticancer effect in human pancreatic carcinoma cells via the inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor.

Vu HA, Beppu Y, Chi HT, Sasaki K, Yamamoto H, Xinh PT, Tanii T, Hara Y, Watanabe T, Sato Y, Ohdomari I. Vu HA, et al. J Biomed Biotechnol. 2010;2010:290516. doi: 10.1155/2010/290516. Epub 2011 Jan 26. J Biomed Biotechnol. 2010. PMID: 21318151 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

162 results

Search Page

Filters